Connect your AI

Sutro Biopharma STRO Accrued compensation and employee benefits

Accrued compensation and employee benefits at other companies

SchrodingerSDGR

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's accrued compensation and employee benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's accrued compensation and employee benefits?: Sutro Biopharma (STRO) reported accrued compensation and employee benefits of -$9.29M in Q1 2026.
How has Sutro Biopharma's accrued compensation and employee benefits changed year-over-year?: Sutro Biopharma's accrued compensation and employee benefits decreased by 587.5% year-over-year, from -$1.35M to -$9.29M.